Annual Funding

Our Institute is one of four Cancer Research UK core funded Institutes, receiving £22.9 million a year. This core funding enables the Institute to provide an outstanding environment in which to train and develop scientists. It also allows Group Leaders to expand their teams and research to explore innovative new ideas.

Along with the CRUK core funding, the research in the Institute is funded by a number of organisations. We currently have 158 active research grants at the Institute, with an extra £4.9 million in CRUK research grants and £12 million from various other funding bodies.

Infrastructure at the Institute is supported by Higher Education Funding Council for England generated income of £2.9 million.

Overall, the total funding of the Cancer Research UK Cambridge Institute for 2018 is £45 million.


    Cancer Research UK
Cambridge Institute Funding 2018

 


With thanks to all the organisations funding research at the Institute:

Aarhus University

Addenbrooke’s Charitable Trust

American Association for Cancer Research

Aprea AB

BBSRC

Breast Cancer Research Foundation

Cambridge University Hospitals NHS Foundation Trust

Cold Spring Harbor Laboratory

EMBO

European Commission

F Hoffman la Roche Ltd

General Sir John Monash Foundation

GlaxoSmithKline

Institut de Recherches Servier

John Hopkins University

Medimmune

National Institutes of Health

Netherlands Organisation for Scientific Research

Pancreatic Cancer UK

Pew Charitable Trusts

Rising Tide

Royal College of Surgeons

Silicon Valley Community Foundation

Sohn Foundation

Susan G Komen

US Department of Defense CDMRP

Wellcome Trust

Academy of Medical Sciences

Agilent Technologies Inc.

Anticancer Fund

AstraZeneca

Bicycle Therapeutics Ltd

British Heart Foundation

Cancer Research UK

CERN

Curesearch

EPSRC

European Research Council

Genentech

Genetics Society

Innovative Medicines Initiative Joint Undertaking

JISC

Mathile Family Foundation

Medical Research Council

National Physical Laboratory

Norwegian University of Science and Health

Pathological Society of Great Britain and Ireland

Prexion Corporation

Rosetress Trust

Royal Society

Sloan Kettering Institute for Cancer Research

St Jude Children’s Research Hospital

US Army

Vall d’Hebron Institute of Oncology